0001104659-21-077405.txt : 20210607 0001104659-21-077405.hdr.sgml : 20210607 20210607081525 ACCESSION NUMBER: 0001104659-21-077405 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210607 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210607 DATE AS OF CHANGE: 20210607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001270073 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223868459 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35668 FILM NUMBER: 21998319 BUSINESS ADDRESS: STREET 1: 10 HUDSON YARDS, 37TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 646-747-1000 MAIL ADDRESS: STREET 1: 10 HUDSON YARDS, 37TH FLOOR CITY: New York STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031113 8-K 1 tm2118923d1_8k.htm FORM 8-K
0001270073 false false false false false 0001270073 2021-06-07 2021-06-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 7, 2021

 

 

 

Intercept Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware

(State or Other Jurisdiction

of Incorporation)

001-35668

(Commission

File Number)

22-3868459

(IRS Employer

Identification No.)

 

10 Hudson Yards, 37th Floor

New York, NY 10001

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: (646) 747-1000

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ICPT   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02(c). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 7, 2021, Intercept Pharmaceuticals, Inc. (the “Company”) announced the appointment of Andrew Saik as Chief Financial Officer, effective June 21, 2021.

 

Since March 2020, Mr. Saik, age 51, has been Chief Financial Officer of Vyne Therapeutics Inc. From 2017 to 2020, he was CFO of PDS Biotechnology Corporation (formerly Edge Therapeutics, Inc.). From 2015 to 2017, he was CFO of Vertice Pharma, LLC. From 2014 to 2015, he was CFO of Auxilium Pharmaceuticals, Inc. From 2013 to 2014, he was Senior Vice President, Finance; and Treasurer at Endo Health Solutions Inc. From 2001 to 2012, he served in senior financial management roles at Valeant Pharmaceuticals International. Mr. Saik holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.

 

In connection with his hiring, Mr. Saik entered into an Employment Agreement with the Company dated as of May 17, 2021. The Employment Agreement provides that Mr. Saik will be employed as Executive Vice President and Chief Financial Officer for the period commencing on June 21, 2021 (or such other commencement date as may be agreed upon with the Company) and ending on the one-year anniversary thereof, with automatic one-year renewals. The Employment Agreement provides that Mr. Saik will be paid an initial annualized base salary of $475,000, and a signing bonus of $102,500 (repayable if employment ends before the second anniversary of the commencement date as a result of termination for cause or resignation other than for good reason), and will be eligible to receive a bonus at the end of a given fiscal year based on a target equal to 50% of his base salary (in 2021, based on his annualized base salary and prorated for time worked). Mr. Saik will be granted as an initial equity award vesting over four years (i) time-based stock options for 72,540 shares exercisable for ten years (vesting 25% after one year and in equal monthly installments over the following three years) and (ii) 52,156 restricted stock units (vesting 25% after one year and in equal quarterly installments over the following three years).

 

The Employment Agreement provides that if employment terminates for any reason (including non-renewal by Mr. Saik of the Employment Agreement, by the Company for cause, death, disability, or by Mr. Saik without good reason), the Company will pay accrued and unpaid salary, benefits, and expenses.

 

In addition, in the event of a termination (i) by the Company’s non-renewal, (ii) by Mr. Saik for good reason, or (iii) by the Company without cause, Mr. Saik will receive (a) 12 months of base salary (payable on payroll), and (b) 12 months of continued participation in the Company’s group health and dental plans, with the Company paying for him and his dependents the portion of the premiums that it paid during the term of employment (or the portion of the premiums associated with COBRA continuation coverage). In the event of such a termination, that number of Mr. Saik’s unvested options and other equity awards that would have vested within one year of termination will vest, and Mr. Saik will have until the earlier of the expiration date of the option or one year from termination to exercise all vested options. However, in the event of such a termination within 12 months following a change in control of the Company, Mr. Saik will instead receive (a) a lump sum of cash equal to 12 months of base salary, and (b) the aforementioned 12 months of benefit continuation, and all of Mr. Saik’s unvested options and other equity awards will vest, and Mr. Saik will have until the earlier of the expiration date of the option or one year from termination to exercise all vested options. In either case, any awards that vest based on attainment of performance measures will be governed by the terms of the applicable award agreement governing termination, or governing termination following a change in control, as applicable.

 

In the event of a termination by Mr. Saik by non-renewal, by the Company for cause, or by Mr. Saik without good reason, all unvested equity awards will be forfeited, and Mr. Saik will have until the earlier of the expiration date of the option or 90 days from termination to exercise all vested options. In the event of a termination by reason of disability, all unvested equity awards will be forfeited, and Mr. Saik will have until the earlier of the expiration date of the option or one year from termination to exercise all vested options.

 

Item 7.01. Regulation FD Disclosure.

 

On June 7, 2021, the Company issued a press release announcing the appointment of Mr. Saik as Chief Financial Officer.

 

A copy of the press release is attached as Exhibit 99.1 and incorporated by reference.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number  		   Description  
99.1   Press Release issued June 7, 2021

 

The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INTERCEPT PHARMACEUTICALS, INC.
     
  By:/s/ Jerome Durso
 Name:  Jerome Durso
  Title:President and Chief Executive Officer

 

Date: June 7, 2021

 

 

 

 

EXHIBIT INDEX

 

Exhibit
Number  		   Description  
99.1   Press Release issued June 7, 2021

 

 

 

 EX-99.1 2 tm2118923d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Intercept Appoints Andrew Saik as Chief Financial Officer

  

NEW YORK, June 7, 2021 – Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Andrew Saik as Chief Financial Officer.

 

Mr. Saik brings more than 20 years of biopharma finance experience to his new role at Intercept. He was previously Chief Financial Officer of Vyne Therapeutics, where he led a buildout of the company’s finance department in the U.S., renegotiated debt obligations to provide the company with enhanced financial flexibility, and helped raise over $135M to fund operations. Prior to joining Vyne, Mr. Saik held CFO positions at PDS Biotechnology, Inc. (formerly Edge Therapeutics), Vertice Pharma, LLC, and Auxilium Pharmaceuticals, Inc. Prior to Auxilium, he was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc., where he helped complete the acquisition of Paladin Labs and restructured $3B of debt into a new corporate structure. Mr. Saik holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.

 

“We are pleased to have Andrew joining our leadership team as CFO at such a pivotal time for the company,” said Jerry Durso, President and Chief Executive Officer of Intercept. “With over 20 years of biopharma finance experience including several recent roles as a public company CFO, he is an ideal leader to help Intercept build on its strong foundation and navigate the next phase of the company’s growth and development. I would also like to take this opportunity to thank Rocco Venezia, our Chief Accounting Officer, for his leadership as Acting CFO.”

 

“I’m thrilled to be joining Intercept and look forward to working with this team to help write the next chapter of the company’s history,” said Mr. Saik. “Intercept’s scientific and commercial capabilities give us a tremendous opportunity to continue building value for all of our key stakeholders in 2021 and beyond.”

 

About Intercept

 

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements, including, but not limited to, statements regarding the progress, timing and results of our clinical trials, including our clinical trials for the treatment of nonalcoholic steatohepatitis (“NASH”), the safety and efficacy of our approved product, Ocaliva (obeticholic acid or “OCA”) for primary biliary cholangitis (“PBC”), and our product candidates, including OCA for liver fibrosis due to NASH, the timing and acceptance of our regulatory filings and the potential approval of OCA for liver fibrosis due to NASH, the review of our New Drug Application for OCA for the treatment of liver fibrosis due to NASH by the U.S. Food and Drug Administration (“FDA”), our intent to work with the FDA to address the issues raised in a complete response letter (“CRL”), the potential commercial success of OCA, as well as our strategy, future operations, future financial position, future revenue, projected costs, financial guidance, prospects, plans and objectives.

 

 

 

 

These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “possible,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement except as required by law. These forward-looking statements are based on estimates and assumptions by our management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks.

 

The following represent some, but not necessarily all, of the factors that could cause actual results to differ materially from historical results or those anticipated or predicted by our forward-looking statements: our ability to successfully commercialize Ocaliva for PBC; our ability to maintain our regulatory approval of Ocaliva for PBC in the United States, Europe, Canada, Israel, Australia and other jurisdictions in which we have or may receive marketing authorization; our ability to timely and cost-effectively file for and obtain regulatory approval of our product candidates on an accelerated basis or at all, including OCA for liver fibrosis due to NASH following the issuance of the CRL by the FDA; any advisory committee recommendation or dispute resolution determination that our product candidates, including OCA for liver fibrosis due to NASH, should not be approved or approved only under certain conditions; any future determination that the regulatory applications and subsequent information we submit for our product candidates, including OCA for liver fibrosis due to NASH, do not contain adequate clinical or other data or meet applicable regulatory requirements for approval; conditions that may be imposed by regulatory authorities on our marketing approvals for our products and product candidates, including OCA for liver fibrosis due to NASH, such as the need for clinical outcomes data (and not just results based on achievement of a surrogate endpoint), any risk mitigation programs such as a REMS, and any related restrictions, limitations and/or warnings contained in the label of any of our products or product candidates; any potential side effects associated with Ocaliva for PBC, OCA for liver fibrosis due to NASH or our other product candidates that could delay or prevent approval, require that an approved product be taken off the market, require the inclusion of safety warnings or precautions, or otherwise limit the sale of such product or product candidate, including in connection with the newly identified safety signal relating to Ocaliva identified by the FDA in May 2020 and with respect to patients with PBC with decompensated cirrhosis, a prior decompensation event or with compensated cirrhosis who have evidence of portal hypertension; the initiation, timing, cost, conduct, progress and results of our research and development activities, preclinical studies and clinical trials, including any issues, delays or failures in identifying patients, enrolling patients, treating patients, retaining patients, meeting specific endpoints in the jurisdictions in which we intend to seek approval or completing and timely reporting the results of our NASH or PBC clinical trials; the outcomes of ongoing discussions with the FDA and European Medicines Agency regarding the feasibility of the COBALT and 401 trials; our ability to establish and maintain relationships with, and the performance of, third-party manufacturers, contract research organizations and other vendors upon whom we are substantially dependent for, among other things, the manufacture and supply of our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our clinical trial activities; our ability to identify, develop and successfully commercialize our products and product candidates, including our ability to successfully launch OCA for liver fibrosis due to NASH, if approved; our ability to obtain and maintain intellectual property protection for our products and product candidates, including our ability to cost-effectively file, prosecute, defend and enforce any patent claims or other intellectual property rights; the size and growth of the markets for our products and product candidates and our ability to serve those markets; the degree of market acceptance of Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH or our other product candidates among physicians, patients and healthcare payors; the availability of adequate coverage and reimbursement from governmental and private healthcare payors for our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our ability to obtain adequate pricing for such products; our ability to establish and maintain effective sales, marketing and distribution capabilities, either directly or through collaborations with third parties; competition from existing drugs or new drugs that become available; our ability to attract and retain key personnel to manage our business effectively; our ability to prevent system failures, data breaches or violations of data protection laws; costs and outcomes relating to any disputes, governmental inquiries or investigations, regulatory proceedings, legal proceedings or litigation, including any securities, intellectual property, employment, product liability or other litigation; our collaborators’ election to pursue research, development and commercialization activities; our ability to establish and maintain relationships with collaborators with development, regulatory and commercialization expertise; our need for and ability to generate or obtain additional financing; our estimates regarding future expenses, revenues and capital requirements and the accuracy thereof; our use of cash, cash equivalents and short-term investments; our ability to acquire, license and invest in businesses, technologies, product candidates and products; our ability to manage the growth of our operations, infrastructure, personnel, systems and controls; our ability to obtain and maintain adequate insurance coverage; continuing threats from COVID-19, including additional waves of infections, and their impacts including quarantines and other government actions, delays relating to our regulatory applications, disruptions relating to our ongoing clinical trials or involving our contract research organizations, study sites or other clinical partners, disruptions relating to our supply chain or involving our third-party manufacturers, distributors or other distribution partners and facility closures or other restrictions, and the impact of the foregoing on our results of operations and financial position; the impact of general U.S. and foreign economic, industry, market, regulatory or political conditions, including the impact of Brexit; and the other risks and uncertainties identified in our periodic filings filed with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020.

 

 

 

  

CONTACT

 

For more information about Intercept, please contact: 

 

Lisa DeFrancesco 

+1-646-565-4833 

investors@interceptpharma.com 

 

Christopher Frates 

+1-646-757-2371 

media@interceptpharma.com 

 

 

Source: Intercept Pharmaceuticals, Inc.

  

 

 

 EX-101.SCH 3 icpt-20210607.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 icpt-20210607_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 icpt-20210607_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2118923d1_ex99-1img001.jpg GRAPHIC begin 644 tm2118923d1_ex99-1img001.jpg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end XML 7 tm2118923d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001270073 2021-06-07 2021-06-07 iso4217:USD shares iso4217:USD shares 0001270073 false false false false false 8-K 2021-06-07 Intercept Pharmaceuticals, Inc. DE 001-35668 22-3868459 10 Hudson Yards 37th Floor New York NY 10001 646 747-1000 Common Stock, par value $0.001 per share ICPT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
Jun. 07, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 07, 2021
Entity File Number 001-35668
Entity Registrant Name Intercept Pharmaceuticals, Inc.
Entity Central Index Key 0001270073
Entity Tax Identification Number 22-3868459
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 10 Hudson Yards
Entity Address, Address Line Two 37th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10001
City Area Code 646
Local Phone Number 747-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ICPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://interceptpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2118923d1_8k.htm icpt-20210607.xsd icpt-20210607_lab.xml icpt-20210607_pre.xml tm2118923d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2118923d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2118923d1_8k.htm" ] }, "labelLink": { "local": [ "icpt-20210607_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "icpt-20210607_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "icpt-20210607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "icpt", "nsuri": "http://interceptpharma.com/20210607", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2118923d1_8k.htm", "contextRef": "From2021-06-07to2021-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://interceptpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2118923d1_8k.htm", "contextRef": "From2021-06-07to2021-06-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-077405-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-077405-xbrl.zip M4$L#!!0 ( .M!QU+/+.CG10, *4, 1 :6-P="TR,#(Q,#8P-RYX M5==WV,AGG0JTZ=FH[A?;7 MS\X'4$@1T(TGY_JR-M6F3D/%XW)#JGHZ5OC4- MII+U]/J6VLQ,Q<))6/[6HY]SPZ;D'7JZ/SZ<7/*?(Y!'68_N_6;7=/=+9_ U M?OQ]N7/]ZW9BDP\[ RKNY,.G^^^$/Z8=EMX-PFO6/SHMCFP9=@,)1>Y52-,. MYLH;[S64'I'=,(S(S_->/\<%!; Y$5S>UL&CX^-CDN]6T"7D9*!%);U'_/: M&I@JNUV^ L^EL52R)_C83@GSX'U2;#Z!\EKH00'E%32&!9P!UABI>^(V''XW MQ&&$]Z(*GAD\HC2=4H;4#'+IDH4'H2'KNT$)"#MF=+)1QC23#CB748%'W*( V2I'H'U'C0I M9;">:.5G*J5RMG>=5T9\+$VY\[4+O&IY S2U$O#=U8'\PO7;RB,\AG24FQP! MXG$[*)9>S$GG3YF66#10C[=LI\F6Z94UID$3PGD1F(O\IW^3K58!PO M+Z+G B6QA#Q#8E2P3&S&F:522RD#U67-KJ]JHDL8HKSYFMX4[P61(5;XLD5@[P MNBS,F(^I3%K]L+EKYXG5PTO\ MLOCO9"VK5*3")O[_RLLRV-:RRWD\[]<6*23=\B]02P,$% @ ZT''4@RX M!/;^"@ X(< !4 !I8W!T+3(P,C$P-C W7VQA8BYX;6S-G5UOX[@5AN\+ M]#^PWIL6&,=Q@A9-=F87&4^R,#:;I+%GMNVB6- 2XPBAR8"2$_O?EY1$6:)X M)"5%2>8BHQ'?0[T4GY#4!ZF//^XV%+T0D2:UCECV?3R:OKZ]'C+_@5RZ>TJ.(;X;EM\APMDVKS(YWQ^5/$?Z1)NSI M7/U:X90@>;98>KY+DT^CVF%?3X^X6$].CH^GDW_^YO:N>82SO-)[#X- MA?K?6,O&:M=X>C(^G1[MTGBD3WY^!@6GY)X\H+R8Y]G^68*4)HJ#4;GO49 ' MNQDJQ$3%3QA9XXS$ZD!GZD#3OZD#?5?NOL8K0D=(*24>8+G.&GF501/79N^( M2'A\R=[GVHSV9%_^[8CL?RA /=YY$98\P_1=YNN1SFW?D/>=\4.<^S,M6WGR MOC-=B_R_V,[:EM]\>NWGE:J=UW*K89'L,ME_D5B;5%ETM,#Y$?*.H:8D.EKSETE,$IGWR;':&*N-\?&T;+&_D[M^GW$Y&KA8 MI9G 4:;SRPOS:61)GYC&E/)":'=81#U%+!63B,L.ZCD;T^)D%N$/@F^LARW+ MSBV)O]-5%5^<''D(P&A#)DC*MR(B;ZJ;NEOH+)6.-E0JU+"*L/'7Q>B'7(-^ MTZK_?)P<EH056TQ9-:TEB"E\5+- M%_+PL;)P1?':4@@CW55%6VWIFFXD!E'5-D=F75<:I$1^*_L+22.1/*MA?E=I M&C+G56\QV2*@I@D+A+8QF(>:UFM3?T_6B>IRE!%U]4O4SHZ&#="[[@PZ;9N] M@U4:;I@;(OI/7GFH@NBILPU.S:3)C)U35"D6(R!@!1: M5(B]]%H*5W3 5@U 3%D03%B]P9B4LE#(&4I,$L3U:3UHM*6 M.K\D ]/:8K9[Y KH@<.DQ MUWH27,@;N'CMDRY9EF1[];;>S7:S(L)2Q+;$%2&0.4V&F1X$$8 IDX1"AI0. M%4*/]:^?-K!,O2H)%LJ4N>7 ;K+)0E,3$ ]68P 3!VW^YJI'+F:RK1*8SEE, M=C^3/5BZELXM&8#-)AJ&*" V[,X .$HQRM5(RCWB<2>2#1;[11+U=!YMH5M M(*--0DQ50(@ U@!&2C5:S&?^^Y8EWLUC"6WRD!3OH?>P NK=(M-CNTD.( X( MH&Z' $]@50,NF5AH7/RA@*?^$?G9"@Z)T&C<_(>=):O/"AT3M]0X%/_ MZ)P.1>S4<5'H!IVW5BLU!%AXT+6]]R*@ M-$1?" &I)[P08P;67'T(8'D-U@'T75<%G'^4>I'+CW M_L%HF9\6IVG2WMP4FO!0:1KK;6@*M7\P[GB:8?KOY+GSDMTN]@*)U; 5E88R M/&!L]OJP*6*0#/)W"5ZBJQZ,6">X&>GNIBI;;!VF*M<2@T#!YJ@]5;FXVU*( M_%2VXE40#+0.S61G56TQ5=5T+2V,BFX;:M5S_CFF MU7WK="]U^JM(,GG\&=]LMJQ\9F1[4Q'0N:KK3INZWJVB(!CHD'A3A %))'5 MD4]35$LEB=N'!^LHH$OL"HU^PQH16!D$*KWV3&1DP#BJ1: B!.4Q(< S3],M M$6]"R!+B"230/(!32Q\B5)#)7K2*0/^$+4BTE?WF?GJR6B89M5V&MB7.>BG M7-5'&>E!$ *8,HG(TQ!_0-.3/Z_^@G24%PAN^%)@M3SN8K]9<0JLIV55N4*A MPZ*FP2() @C8E\G$#4>E%!5:?^MM-2Q;"F6DN\+ :DL#T$@,HNIMCEH-0:/& MO78"E[OH45HCP-0(N\QU9V S:78(=4T0('08:UVXE%*DM?ZF1ARZLG7_X&#M M;7"P[ADRI;I=T62-@048.]6NT>BP;%)BD08% M#.P/;#^J$'2(\;-V9[Z F_I @=CD+J[DAJ6L@,[9ZIU=-JOE.VVB($CI6'\!FDQM# M%! O=F< )Y48%6J?T\F+U2^J(5CQ12:PF)#<\>3R3M/&''.K-B!R.@U",\[+ M-4L.(^%[X1,SD06_..-]4-E?OE;UH6VRO@5)* (+'YZE@'1R"M]4C$8H,I M_;Q-$T92N&LR5&Z)L%IL$M&0!$2$S1= 1"Y%6NN1B,L-$6O9[?TD^&OV6*Y* M"Y804+LEI--RDQ2K-"!BNOP!Y.@05,3HA81](K0[+*Q>K"<)E]4H.R1H,OR\WWU%?&+?/Q^@R6*U 2-8N3. M8BQL('6)G7^/!33<^BI+2QD$3KWVX"^T5!%(AWAAYU;R+.I7?+F5>48VX+R+ M_A!7' TUKVGJTP?!U$"3)EEY6/,R/ ]$*M+_RDSUI?[A 6!#Y'C<;#%H#)MK MBB!( 6U!@^;ZEQ-\K@RX7=$DNJ("1X2H-[K2JOWJNVLW,-HM.6\J4I.I0:$!T?86OP"' MARQ0+8\/M3[,_RU ]>*Z6JN.1T^+1RQ/X^TV2U7/*NW!]]$[@QP_H!A0 .,Q M14=$0 .L D]LL@C41[Z 17!J!;M]1HN/:QT2.+/^WOR0(2: ;$DN^RS/-Q3 MQU7(@%C75WB#BV->\/4&!H'B6]U"EX,IJF> 5NI-M#(+])O*!.6YV+X-7]]U M+;?D;KU+_EKAE,@]_P502P,$% @ ZT''4HB?FD]>!P 0UD !4 !I M8W!T+3(P,C$P-C W7W!R92YX;6S-G%MSVC@4Q]]W9K^#ESYSS?82FFPGH:'# M-$VR@;:[^](1M@!-9(F1Y #??B4;*!=+/KST) \),4?2^?^.+/M8DB\^+%,> M/5.EF127M7:C58NHB&7"Q/2R]G58OQKV!H-:I T1">%2T,N:D+4/?_W^6V1_ M+OZHUZ,^HSSI1A]E7!^(B7P?W9&4=J-/5%!%C%3OHV^$9^Z([#-.5=23Z9Q3 M0^T71N^S4FFD:6EM#=I6:7M9UF%V<-J:;-3JO5;O[S MY788SVA*ZDPX:C&M;4JY6LK*M<_/SYOYMQO3(\OE6/%-&V?-C3O;FNVW+&"_ MXXEF79V[=RMC8O*@5S83>2WF\KF94&;I=UKN M@\/1JK?::^:O[*$?>7-78VT4BM_+ V!R;-7^;;ALK(UEONVK[% MH6>[<;Q2<2150I7EOJF+J'@O>L===FW1G!-E*ZK',\:W@9\HF?H8K7E(CZ.[ MN&P3OY+IE?4B<9[T.9F60STP 5)M8V M58/+]2/5L6)S1Z<"[YXED'('E7*) M-A38F[/ID4Z9\]HYY"[-U!T,CQ2>(D#\9YAC1U M:ARNA,@(?Z1SJ2KP[UL" MJ?^)2;U,&RKLOS.B[%T&7T%X'QD#D;_&1.Y1B$I]I(C0S%&"8#^V!G)_@WIS MXM&("GXXHYR[)) (4(\OLP?"?XL)WZ_SQ>"_>7;W /;" X_ 3A%@$-Z]E" < MJ46-PP-53";VLJ\ $3@R!K(_QV3O4?@"J-^(!,I\:PK.FO"1'\A#!=YG.B:\ M\*MOC^DP]!)S*'B4?+52Y@N _R\E"HQ^QQ@*'B6%K9"(@KV7*;7G4G"<\5M# MP:,DKU4B4#V7WBQU90TB@)JT\4(N'-$PMAW/1)B/*A M)90T2IX:$H=(NV=5*<('(J'+SW05PGUD"N6-DI\&Y2$"?U L)6HU9''U,')L M"T6.DI6&!2(R'Y'E(+':V(054Y+5Z+U%H!% 24E!_7BO1G+AF?_V&D/!H^2Q%1+Q ML>?7H7OUH.0S*U9O5;$_*@$- &)Z&Q:+'X7UC0"DYV\LH=014]UR MMX!B14E>R\2@4+V5;IYE)D7P2>^Q%90N2A;J$X4S(+OUT-H[&.Q\#5YCAS+< M'LI @?E=,6/]Z,DTS<3ZB8]G'LYC"H6,DCH&Y:$ 'TK.8F:8F'ZQ=Y2*$5Y. MN\P.BAHE4?0+0^'\H*B+.K4WZ_E*,[>%0MU/)KX1.60/Y8Z2)U8+?0G\!UIG M5)T:A9)2T%B@I(Q0T3@C#XTS.QRNVIWQR.T'\HP[1U90XBCIHD\4"N$[.5+$ M[4T0H:DZ/\0 M)O> 5)R=BOF&)K>K7:6Y-WW[H1R^QQ2*'6=+:$@>#O L888FA6-])HB(;3JV MW<'GR>^K2T'#@+-G%"@:<1+A.^7\LY +,:1$2T&3(D$(S2-XBT!C@3AW62$7 M,1#?),\L*Y4O7E6>\\%C"@6/.&?ID8>Y4K18E+V],A6O-0EQ]Y6 XD>&4.:(RW=+ MI2&B'J:$\^M,,T%U<+0Y,(2B1ERG6RH-$?5-2M74#G:?E%R8V7I':PBYIP 4 M/>)JW*!4S! L?^ZG+W;Z!?F76(/?U8 (WRL2]X4D<>P6=A17>Y$0Y6$?LH?2 M1]U(ZA>*PO_>S*C:O=/*71K8G"^T_**Z%#06**DN5#3FE7?GO0;!"^^>'90Z M8E);)@QS1U@VYBSNM M H2CWBGIGYO9:'*]>J03JMR"B1%=FFO;W%/XQ@E0'!HEU+:3K MUAYP[P,NOG&_W#MO[9'_ 5!+ P04 " #K0<=2Y;]87=L8 !VEP $@ M '1M,C$Q.#DR,V0Q7SAK+FAT;>T]:5?BR-K?/(ID@)*0Q*S(/2O?Y^G*H$$@J*MT]ACSW0KI)9GWVK)SO^&?9,, MF.MQV_J<4?-*AC!+MPUN=3]G K^3V\S\K[:ZLM/SH1VTM;S/F9[O.UN%PL/# M0_ZAF+?=;D&M5JN%(;;)R$9;P]1VFJ*HA>N3XY;>8WV:XY;G4TMGXTXFM^[F MCX]/QTW;KLD33?&;:))B869H>&I,.L0;5PKR8:*IG]JT+)OZ45/NV25-W7@, M#MEBW&$XKZV*, .&['KOXGC2W$]O/VE:\%UJ>1W;[5,?>(@CE7.*EM,JL4%R M'M,3 \'G?-<>/#G.9JZH1N/,,">)*3YN4V],<8--D3N:$QY #TW)*6IL=)=U MY@Y>*<#3J&'@Y;J4.N/&'>JU1:E]A%/4CKI=F#Y[B@=A_!A M2C?/]6>G@2]3FG+=F;3EEL]?/F=\-O0+4E$+V*\0 M#KOS?[D<.>#,-+9(B_G;Y)3VV189&L-MTMP7O]PH6O7F6^N3MO]E=_<Q>(,8WZ1@>A-A^HSA2I5QKY=T+Y=O&$@BH '_-RP@Y*@.%'*IV;0, M-OS*1C<*6"MM0U$VBL\9MQH;=[?/+ /^^@/3/8Y MTP$IW"*JXOCDDO>AR2E[(!=VGUI9^446 '!Y1\B[P0=1/X-[CDE'6\2R+28> M\N$6"BYS42/$)VX8S!+Z@1^AX6G0A[%T*?I#_P+MRX%K]U%6JMM@RFBEA"3.#P)*[W XOKPC=X;P]#,0Y#RS:YSGT(24XH MF Y.S;<'H!0'X-QE2 (C!BRX1+8P=RS3H>Y;P](^1% FIX7,'=!< H)+4'H MP*DR%\?R9 OTX%N>",T 3"+BK:V><,QHN'.1E+SOF$RZ ME'"JY.!R.L\.W&@V:"9,QE9(&('X(X2)7%_4C0DE'7\[_IX;^*3#F4L$*BPU M[JDWOR85>KKS9+I"ZGSA; [0US9FH8#@T_7W05IK$Q2BD2;/9KH!)^=TBIY, M@Y4 (/HR)&F2SJ"^DLA@K6>HV6?4"UQ6"\WZ%K2)!HL>):? T>:,+WW$W"E" M(HA&+YYCXHMFY@&_ 6R(I>Z4X#^\!/_VW$B-]RG;I=;6P3\=Z:VXSG4 M>KYC_\^_U(JRO5/ WA"_.K7Y$XB'R?#D(C!9[IQV1105CQ!DSYQO.]![FX0? MV[;OVWWQS0,W_!Z"J'S*)'JV;1=PECWW3*K?$0VP\,#E&-LD?!B-(Y^KD^>( M=\[C/R!<4A'F"#ND7OAO#/I" OR_A;;Q*<*!2D\-M$W0>.2HR;L D,XP7!^3 M5%+8\6=I_!. [[1KWTZ;EXW]U976Y>YEH[53:-?>)QZM1OW;1?.RV6BMKNR> M[I/&=?UP]_1+@]3/3DZ:K5;S['01Y)Z<[)<@]R?U>A"%^;:575W9S]?S1%/* MI>H[16@Q=7E3P)]OXK9($0"B@6^/;9I6?M*DO8G)^AL(% 'WKDS P=G%"0 K M^H?1_$U5V11E@5QNW]8#D41 X'RCCRL8DUK&C^K)MW;]XGN_].<=C/>SR6Q\ MODQM,_=U.CD8*\"'$G\H\2]0XB44*E!B\.(7C=/+U96+QOG9Q>4[U0Y )*+^ M>X7_/'"]@%K^ZHIOP]^S](@@X!2[W.?-65QI# MO4'QGWEQ4X_7DLV8*8^].L9 M=#0"R)F5%A0D ,O4C@*+D8TLP4'GA@GOCJ%+((D?(<*[BO.?G$\8[FFM5T.M ME\M'%ZS+/5Q3]W$Y+5WI_^I=WFIWWOFQVWN%2#]MWDRM&:VVKJZJ3E,!VK^P;A%JD#-0">]5? ,E:\ MPUKC+-*_WG8M N(_Q$HM0(HI>^33MLG@H6D"'W2Q-4K)B,\.-8SH\PP@!0L= MLOD4/"&!=-LTJ>,!):+?8N3)4>,V\'RY AY][[O,UWOX'4XS5>-&L*-E@1W? MB* +VQ2+R*6E$O44BUI.6%2P5K8+,9=8@V[Y$+'4Y2ZO0/P[Q^BC@R8P"99L;B4 MOPL_H22D_)(.F^$^#KE?Z3&1;S9:^I>O:N.>55]-Y.< D*EI6JZX6=DLE:OO M7 &:%ZT);(V^8]HCYKX#P)-LB6F%G9]1"?A';H40T5_MM\T,?D')\_$X;]

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end